Sana Biotechnology (SANA) Stock Price, News & Analysis

Company Overview

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9. Sana’s ex vivo pipeline includes allogeneic cell programs designed to target hematologic malignancies and solid tumors, while its in vivo portfolio focuses on directly delivering therapeutic genes to tissues for the treatment of hereditary diseases. Preclinical research efforts span multiple therapeutic areas, with a view to advancing candidates into human trials.

Founded in 2018 as an independent enterprise originating from the life-science incubator Flagship Pioneering, Sana Biotechnology is headquartered in Seattle, Washington, with research and development facilities in Cambridge, Massachusetts. Its global operations support collaborative partnerships and research alliances aimed at accelerating the translation of cell therapies from the laboratory to the clinic.

Under the leadership of Chief Executive Officer Steve Harr, Sana has assembled a multidisciplinary management team with expertise in biotechnology, immunology and drug development. The company continues to expand its scientific and manufacturing capabilities while advancing a pipeline intended to address unmet medical needs and improve long-term patient outcomes.

Key Stats

• Today's Range: $3.75 to $3.93
• 50-Day Range: $2.84 to $5.13
• 52-Week Range: $1.26 to $7.30
• Volume: 2.05 million shs
• Average Volume: 5.62 million shs
• Market Capitalization: $926.25 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.50
• Consensus Rating: Buy

Sana Biotechnology Stock Analysis - MarketRank™

Sana Biotechnology scored higher than 66% of companies evaluated by MarketBeat, and ranked 337th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

Sana Biotechnology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Sana Biotechnology has a consensus price target of $7.50, representing about 97.5% upside from its current price of $3.80.

Amount of Analyst Coverage

Sana Biotechnology has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Sana Biotechnology are expected to grow in the coming year, from ($1.16) to ($0.84) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Sana Biotechnology is -3.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sana Biotechnology is -3.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Sana Biotechnology has a P/B Ratio of 3.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

19.95% of the float of Sana Biotechnology has been sold short.

Short Interest Ratio / Days to Cover

Sana Biotechnology has a short interest ratio ("days to cover") of 5.4.

Change versus previous month

Short interest in Sana Biotechnology has recently decreased by 4.54%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Sana Biotechnology does not currently pay a dividend.

Dividend Growth

Sana Biotechnology does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

19.95% of the float of Sana Biotechnology has been sold short.

Short Interest Ratio / Days to Cover

Sana Biotechnology has a short interest ratio ("days to cover") of 5.4.

Change versus previous month

Short interest in Sana Biotechnology has recently decreased by 4.54%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.9 / 5
• News Sentiment: 1.06

News Sentiment

Sana Biotechnology has a news sentiment score of 1.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 18 news articles for Sana Biotechnology this week, compared to 10 articles on an average week.

Search Interest

52 people have searched for SANA on MarketBeat in the last 30 days. This is an increase of 189% compared to the previous 30 days.

MarketBeat Follows

10 people have added Sana Biotechnology to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Sana Biotechnology insiders have not sold or bought any company stock.

Percentage Held by Insiders

30.10% of the stock of Sana Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

88.23% of the stock of Sana Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SANA Stock Analysis - Frequently Asked Questions

How have SANA shares performed this year?

Sana Biotechnology's stock was trading at $1.63 at the start of the year. Since then, SANA stock has increased by 132.9% and is now trading at $3.7970.

How were Sana Biotechnology's earnings last quarter?

Sana Biotechnology, Inc. (NASDAQ:SANA) issued its earnings results on Monday, August, 11th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.04.

When did Sana Biotechnology IPO?

Sana Biotechnology (SANA) raised $322 million in an IPO on Thursday, February 4th 2021. The company issued 15,000,000 shares at $20.00-$23.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan and BofA Securities acted as the underwriters for the IPO.

How do I buy shares of Sana Biotechnology?

Shares of SANA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Sana Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Sana Biotechnology investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Walmart (WMT).

Company Calendar

• Last Earnings: 8/11/2025
• Today: 10/02/2025
• Next Earnings (Estimated): 11/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SANA
• CIK: 1770121
• Web: sana.com
• Phone: 206-701-7914
• Fax: N/A
• Employees: 380
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Sana Biotechnology: $7.50
• High Price Target: $12.00
• Low Price Target: $5.00
• Potential Upside/Downside: +93.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.06)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$266.76 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -91.96%
• Return on Assets: -43.07%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.47
• Quick Ratio: 2.47

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.12 per share
• Price / Book: 3.47

Miscellaneous

• Outstanding Shares: 237,810,000
• Free Float: 166,226,000
• Market Cap: $923.89 million
• Optionable: Optionable
• Beta: 1.91